Diabetic Ketoacidosis in a Patient with Long-term Clozapine Therapy

2007 ◽  
Vol 22 (5) ◽  
pp. 376 ◽  
Author(s):  
Youn Joo Jeon ◽  
Seung-Hwan Lee ◽  
Se-Na Jang ◽  
Eun-Sun Kim ◽  
Jeong-Yo Min ◽  
...  
Author(s):  
Tom Burns ◽  
Mike Firn

This chapter focuses mainly on the importance of maintenance antipsychotic medication and mood stabilizers. It examines procedures to support persistence with these drugs and maintain engagement. The techniques for initiating and monitoring clozapine therapy in the community for patients with resistant schizophrenia are outlined. The practical processes for ensuring and conducting regular structured reviews of long-term medication, both to assess progress and to identify side effects, are described in detail. In addition, the judicious use of antidepressants and benzodiazepines is outlined.


1999 ◽  
Vol 23 (11) ◽  
pp. 656-657 ◽  
Author(s):  
Thomas R. E. Barnes

Pereira et al's paper (1999, this issue) is to be welcomed in that it highlights an area of clinical decision that requires a careful balance of short- and long-term risks and benefits in the individual patient. In this (necessarily) brief commentary I will concentrate on this aspect, and leave aside any ethical and medico-legal considerations.


2019 ◽  
Vol 10 ◽  
pp. 204201881882220 ◽  
Author(s):  
Zohar Landau ◽  
Galit Kowen-Sandbank ◽  
Daniela Jakubowicz ◽  
Asnat Raziel ◽  
Nasser Sakran ◽  
...  

Objective: We examined short and long-term outcomes of bariatric surgery in patients with obesity and type 1 diabetes mellitus (T1DM). Methods: We reviewed the records of all adults insured by Maccabi Healthcare Services during 2010 -2015, with body mass index (BMI) ⩾30 kg/m2 and T1DM; and compared weight reduction and glucose control according to the performance of bariatric surgery. BMI and glycated hemoglobin (HbA1c) levels were extracted for baseline and every 6 months, for a mean 3.5 years. Results: Of 52 patients, 26(50%) underwent bariatric surgery. Those who underwent surgery were more often female and with a longer duration of diabetes. Immediately postoperative, 4(15%) developed diabetic ketoacidosis, while 6(23%) experienced severe hypoglycemic episodes. The mean BMI decreased among surgery patients: from 39.5±4.4 to 30.1±5.0 kg/m2 ( p < 0.0001); and increased among those who did not undergo surgery: from 33.6±3.9 to 35.1±4.4 kg/m2 ( p = 0.49). The mean HbA1c level decreased during the first 6 months postoperative: from 8.5±0.9% to 7.9±0.9%; however, at the end of follow-up, was similar to baseline, 8.6±2.0% (p = 0.87). For patients who did not undergo surgery, the mean HbA1c increased from 7.9±1.9% to 8.6±1.5% ( p = 0.09). Conclusions: Among individuals with obesity and T1DM, weight loss was successful after bariatric surgery, but glucose control did not improve. The postoperative risks of diabetic ketoacidosis and severe hypoglycemic episodes should be considering when performing bariatric surgery in this population.


1998 ◽  
Vol 29 (1) ◽  
pp. 170 ◽  
Author(s):  
Robert M. Hoffmann ◽  
Stefan Ott ◽  
Klaus G. Parhofer ◽  
Reiner Bartl ◽  
Gerd R. Pape

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i422-i422
Author(s):  
Junzhe Chen ◽  
Ying Tang ◽  
Honghui Zeng ◽  
Qiuyan Huang ◽  
Yanchun Xu ◽  
...  

2002 ◽  
Vol 36 (6) ◽  
pp. 1012-1015 ◽  
Author(s):  
Nick C Patel ◽  
Peter G Dorson ◽  
Tawny L Bettinger

OBJECTIVE: To report a patient who suddenly developed agranulocytosis after long-term clozapine therapy. CASE SUMMARY: A 41-year-old white man suddenly developed agranulocytosis after 89 months of nearly continuous clozapine therapy. During this time, which included the addition of risperidone to the treatment regimen, his white blood cell (WBC) and granulocyte counts remained stable. One week after having stable hematologic counts, the patient suddenly developed agranulocytosis. WBC and granulocyte counts returned to baseline shortly after discontinuation of all medications and administration of sargramostim. DISCUSSION: The main factor limiting the use of clozapine as a first-line agent in mentally ill patients is the risk of agranulocytosis. Although the greatest risk of developing this adverse reaction is during the initial 6-month exposure, clozapine-induced agranulocytosis continues to pose a risk after years of exposure. Current product labeling requires weekly WBC and granulocyte monitoring for the first 6 months of treatment with clozapine, which may be decreased to biweekly monitoring after 6 months. Based on the sudden and late onset of agranulocytosis in our patient, clinicians may consider opting for weekly monitoring of hematologic function for patients on long-term clozapine therapy. The likelihood that clozapine was the cause of the agranulocytosis was rated possible according to the Naranjo probability scale. CONCLUSIONS: Clinicians must remain vigilant to trends in WBC and granulocyte counts and may wish to consider weekly hematologic monitoring regardless of duration of clozapine therapy. Patient and treatment system compliance with the registries' protocol regarding WBC monitoring is instrumental in reducing morbidity and mortality rates associated with clozapine use.


2003 ◽  
Vol 160 (12) ◽  
pp. 2241-a-2242 ◽  
Author(s):  
HEIDI J. WEHRING ◽  
DEANNA L. KELLY ◽  
RAYMOND C. LOVE ◽  
ROBERT R. CONLEY

Sign in / Sign up

Export Citation Format

Share Document